Mechanisms of Action | Investigational Inhibitors in Lung Cancer
Frontiers | Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
Safety and Tolerability of c-MET Inhibitors in Cancer. - Abstract - Europe PMC
Capmatinib | Uses, Brand Names, Mechanism Of Action
Cancers | Free Full-Text | Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies
A New Type of Recyclable: Finding New Uses for Established Drugs｜Tokyo Medical and Dental University, National University Corporation
Dual inhibition of Akt and c‐Met as a second‐line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells - Han - 2017 - Molecular Oncology - Wiley Online Library
Frontiers | Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report
The c-Met inhibitor capmatinib alleviates acetaminophen-induced hepatotoxicity | Request PDF
Frontiers | HGF/c-Met Axis: The Advanced Development in Digestive System Cancer
Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies - Cancer Treatment Reviews
The METeoric rise of MET in lung cancer - Friedlaender - 2020 - Cancer - Wiley Online Library
Amivantamab mechanisms of action | Download Scientific Diagram
New Drug Product: Tabrecta - MPR
Mechanisms of Action | Investigational Inhibitors in Lung Cancer
The novel c-Met inhibitor capmatinib mitigates diethylnitrosamine acute liver injury in mice - ScienceDirect
Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer - ESMO Open
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping - ScienceDirect
The METeoric rise of MET in lung cancer - Friedlaender - 2020 - Cancer - Wiley Online Library
Kinase Inhibitors and Atrial Fibrillation: Mechanisms of Action and Clinical Implications | JACC: Clinical Electrophysiology
Overcoming therapy resistance in EGFR-mutant lung cancer | Nature Cancer
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances - touchONCOLOGY
The role of MET in chemotherapy resistance | Oncogene
Capmatinib for the treatment of non-small cell lung cancer
